Peter Schulam to serve as interim center director

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Peter Schulam, professor of urology and chief of Yale’s Department of Urology, will serve as the interim director of Yale Cancer Center and physician-in-chief at Smilow.

Lynch joined Yale Cancer Center as director in 2009 and assumed the role of inaugural physician-in-chief at Smilow, which opened that year. During his tenure, more than 130 scientists and clinicians joined the institutions, new-patient volume grew from 3,500 to 9,000 through key affiliations, and participation in therapeutic clinical trials grew by 325 percent.

The center also renewed its NCI Comprehensive Cancer Center Grant, and joined the NCI’s National Clinical Trials Network and the National Comprehensive Cancer Network.

Schulam joined in 2012 as inaugural chief of the Department of Urology at Yale-New Haven Hospital and chair of the department at Yale School of Medicine, where he has established a multidisciplinary team in urologic oncology. He has implemented a program for MRI-fusion guided biopsy of prostate cancer and leads a research program focused on prostate cancer imaging. In addition, he co-founded the Yale Center for Biomedical and Interventional Technology.

YOU MAY BE INTERESTED IN

By law, the Food and Drug Administration is required to determine whether a drug, device, biologic, or medical device is “safe and effective.” But the FDA determination does not control whether the Centers for Medicare & Medicaid Services will pay for it.  To satisfy CMS, medical products and services must be “reasonable and necessary,” meaning...

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease.  The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login